Vaccine platforms to control arenaviral hemorrhagic fevers

Ricardo Carrion, Peter Bredenbeek, Xiaohong Jiang, Irina Tretyakova, Peter Pushko, Igor S. Lukashevich

    Research output: Contribution to journalArticle

    15 Scopus citations

    Abstract

    Arenaviruses are rodent-borne emerging human pathogens. Diseases caused by these viruses, e.g., Lassa fever (LF) in West Africa and South American hemorrhagic fevers (HFs), are serious public health problems in endemic areas. We have employed replication-competent and replication-deficient strategies to design vaccine candidates potentially targeting different groups "at risk". Our leader LF vaccine candidate, the live reassortant vaccine ML29, is safe and efficacious in all tested animal models including non-human primates. In this study we showed that treatment of fatally infected animals with ML29 two days after Lassa virus (LASV) challenge protected 80% of the treated animals. In endemic areas, where most of the target population is poor and many live far from health care facilities, a single-dose vaccination with ML29 would be ideal solution. Once there is an outbreak, a fast-acting vaccine or post-exposure prophylaxis would be best. The 2nd vaccine technology is based on Yellow Fever (YF) 17D vaccine. We designed YF17D-based recombinant viruses expressing LASV glycoproteins (GP) and showed protective efficacy of these recombinants. In the current study we developed a novel technology to clone LASV nucleocapsid within YF17D C gene. Low immunogenicity and stability of foreign inserts must be addressed to design successful LASV/YFV bivalent vaccines to control LF and YF in overlapping endemic areas of West Africa. The 3rd platform is based on the new generation of alphavirus replicon virus-like-particle vectors (VLPV). Using this technology we designed VLPV expressing LASV GP with enhanced immunogenicity and bivalent VLPV expressing cross-reactive GP of Junin virus (JUNV) and Machupo virus (MACV), causative agents of Argentinian and Bolivian HF, respectively. A prime-boost regimen required for VLPV immunization might be practical for medical providers, military, lab personnel, and visitors in endemic areas.

    Original languageEnglish (US)
    JournalJournal of Vaccines and Vaccination
    Volume3
    Issue number7
    DOIs
    StatePublished - Nov 1 2012

    Keywords

    • Arenaviruses
    • Junin
    • Lassa
    • Macupo
    • VEEV TC-83-based replicons
    • Vaccines
    • YF17D Lassa
    • YF17D vector

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology
    • Drug Discovery
    • Virology

    Fingerprint Dive into the research topics of 'Vaccine platforms to control arenaviral hemorrhagic fevers'. Together they form a unique fingerprint.

  • Cite this

    Carrion, R., Bredenbeek, P., Jiang, X., Tretyakova, I., Pushko, P., & Lukashevich, I. S. (2012). Vaccine platforms to control arenaviral hemorrhagic fevers. Journal of Vaccines and Vaccination, 3(7). https://doi.org/10.4172/2157-7560.1000160